Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/41665
metadata.artigo.dc.title: Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
metadata.artigo.dc.creator: Zhu, Zhen
Lu, Zhaohui
Xu, Tianmin
Chen, Cong
Yang, Gang
Zha, Tao
Lu, Jianchun
Xue, Yuan
metadata.artigo.dc.subject: COVID-19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Ct value
Antiviral therapy
Pneumonia
metadata.artigo.dc.publisher: Elsevier
metadata.artigo.dc.date.issued: Jul-2020
metadata.artigo.dc.identifier.citation: ZHU, Z. et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. Journal of Infection, [S.l.], v. 81, n. 1, p. e21-e23, July 2020.
metadata.artigo.dc.description.abstract: Lopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400 mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2 g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19.
metadata.artigo.dc.identifier.uri: https://www.sciencedirect.com/science/article/pii/S0163445320301882
http://repositorio.ufla.br/jspui/handle/1/41665
metadata.artigo.dc.language: en_US
Appears in Collections:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.